Revance Therapeutics And Lyophilization Services Of New England On Apr. 6 Entered Commercial Supply Agreement Under Which LSNE Will Serve As Non-Exclusive Manufacturer And Supplier; Revance Responsible For Est. $28M In Costs

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!